Registration Dossier

Ecotoxicological information

Long-term toxicity to aquatic invertebrates

Currently viewing:

Administrative data

Link to relevant study record(s)

Description of key information

In a 21 -d long term toxicity study to aquatic invertebrates of the test substance, the daphnia magna exposed to 15 mg a.i./L had statistically reduced survival. In this study, the most sensitive endpoints were reproduction and growth. The NOEC for reproduction was considered to be 1.9 mg a.i./L. The LOEC for reproduction is 3.8 mg a.i./L. The LOEC and the NOEC for growth were determined to be 3.8 mg a.i./L and 1.9 mg a.i./L, respectively. 

Key value for chemical safety assessment

EC10, LC10 or NOEC for freshwater invertebrates:
1.9 mg/L

Additional information

A static-renewal life-cycle toxicity test with the claoceran (daphnia magna) was conducted according to the procedures outlined in the U.S. Environmental Protection Agency Series 850 - Ecological Effects Test Guidelines OPPTS Number 850.1300; Standard Evaluation Procedure, Daphnia magna Life-Cycle (21-Day Renewal) Chronic Toxicity Test; and ASTM Standard El 193-87, Standard Practice for Conducting Renewal Life-Cycle Toxicity Tests with Daphnia magna.

Daphnia magna exposed to the test substance for 21 days at a concentration of 1.9 mg a.i /L showed no statistically significant reductions in survival, reproduction or growth as compared to the negative control. Daphnia magna exposed to 15 mg a.i./L had statistically reduced survival. In this study, the most sensitive endpoints were reproduction and growth. Daphnia magna exposed to 3.8 and 7.5 mg a.i./L had statistically significant reductions in the number of young produced, mean length and mean dry weight. The LOEC for this study, based on reproduction and growth, was 3.8 mg a.i./L. The NOEC was 1.9 mg a.i./L and the MATC was calculated to be 2.7 mg a.i./L. Daphnia magna exposed to 0.94 mg a.i./L did show a statistically significant decrease in reproduction. However, this reduction was not considered to be treatment-related due to lack of adverse effects in the 1.9 mg a.i./L treatment group.